Beam Therapeutics Inc.

beamtx.com

What Do They Do?

Develops base-editing genetic medicines and delivery technologies for patients with serious diseases, including inherited blood and genetic disorders.

How Do They Make Money?

Beam receives upfront fees under license agreements; it may count revenue from those fees in later periods as it fulfills the related agreements.

FY2025 revenue

Who Are Their Customers?

Beam aims to partner with other companies to extend its genetic-medicine platform beyond its internal programs.

Do Revenues Turn Into Profits?

No. It lost $80M in FY2025.

Operating income, FY2025

−275% of revenue

▼ −8% (Loss) vs FY2024 (−$415.6M, −654%)

Net income, FY2025

−57% of revenue

▼ −79% (Loss) vs FY2024 (−$376.7M, −593%)

Free cash flow, FY2025

−258% of revenue

▲ +1% (Loss) vs FY2024 (−$356.2M, −561%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −94%; vs $8.5M in Q2 FY2025
Net income: ▲ +20% (Loss); vs −$102.1M in Q2 FY2025

Growing. Revenue grew 2.7x in 4 years, from $51.8M in FY2021 to $139.7M in FY2025, about 28% a year.

Sickle cell delivery strategy The older report described both ex vivo and in vivo delivery across programs; the latest report prioritizes in vivo delivery to stem cells for the next wave of sickle cell treatment.

Who Do They Compete With?

Competes with Life Edit, Metagenomi, Revvity, Aurora Therapeutics, Mammoth Biosciences, YolTech Therapeutics, HuidaGene Therapeutics, Intellia Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Genetix Biotherapeutics, Novartis Pharmaceuticals, Kamau Therapeutics, Fulcrum Therapeutics, Tessera Therapeutics, Cimeio Therapeutics, Agios Pharmaceuticals, Wave Life Sciences, Prime Medicine, and Moderna

Comments